肺癌，血管新生，Protein Kinase抗化劑:藥物開發策略分析 是由出版商BioSeeker Group AB在2012年05月所出版的。
這份英文市場調查報告書包含5967 Pages 價格從美金5175起跳。
本報告提供肺癌的藥物開發策略及以血管新生，Protein Kinase抗化劑的機制、目標、影響領域為焦點，彙整各自的藥劑目標策略，化合物策略競爭基準，開發平台及最佳投資組合計劃等彙整資料，為您概述為以下內容。
第1章 肺癌
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的肺癌治療目標討論
- 新藥的上市:各開發階段肺癌治療藥物的藥劑目標策略
- 使用中的化合物策略:各類型化合物競爭基準
- 治療藥物的適應症選擇
- 開發平台·最佳投資組合計劃:肺癌治療藥物開發平台的競爭基準
- 免責聲明
- 藥品目錄
- 企業目錄
- 圖表
第2章 血管新生
- 本報告的範圍
- 為達成最高治療效果及投資報酬率治療目標檢討
- 新藥的上市:影響血管新生的癌治療藥目標策略
- 使用中的化合物策略:影響血管新生各化合物策略的治療樂物競爭基準
- 影響藥品作用的血管新生的癌症症狀
- 開發平台和最佳投資組合計劃:影響癌症治療藥開發平台血管新生的競爭基準
- 免責聲明
- 藥品目錄
- 企業目錄
第3章 Protein Kinase抗化劑
- 本報告的範圍
- 為達成最高治療效果及投資報酬率治療目標檢討
- 新藥的上市:Protein Kinase抗化劑開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:各類型化合物的競爭基準
- Protein Kinase抗化劑的癌適應症症狀選擇
- 最佳投資組合計劃:Protein Kinase抗化劑開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
Abstract
Product Description
This triple analysis focuses on cancer drug development strategies in Lung
Cancer and by the two mechanism/target/effect areas of Angiogenesis and
Protein Kinase Inhibitors. Each of these three individual parts is evaluated
according to standardized criteria in a five pillar pipeline drug assessment
methodology to compare drug development strategies in oncology. This makes it
easy to find and compare analysis not only within one single cancer focus area
but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development
strategies for 416 lung cancer drugs within the portfolio of 218
investigators, from Ceased to Marketed. This part extensively analyses their
241 identified drug targets, organized into 237 drug target strategies, and
assesses them in eight different compound strategies and and three
subindications of lung cancer.
Part II: Angiogenesis
The angiogenesis report part comprises defined and up to date development
strategies for 239 drugs affecting angiogenesis in oncology within the
portfolio of 148 investigators, from Preclinical to Marketed. This report part
extensively analyses 174 identified targets of angiogenesis affecting drugs,
organized into 167 drug target strategies, and assesses them in 64 different
cancer indications.
Part III: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development
strategies for 409 protein kinase drugs (990 projects) within the portfolio of
160 investigators, from Ceased to Marketed. This report part extensively
analyses 133 identified targets of protein kinase drugs, organized into 200
drug target strategies, and assesses them in 57 different cancer indications.
The report is written for you to understand and assess the impact of
competitor entry and corresponding changes to development strategies for your
own portfolio products. It helps teams to maximize molecule value by selecting
optimal development plans and manage risk and uncertainty. The report serves
as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug' s properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area
strategies
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally
to PPP and to stakeholders across your own organization. The report will also
be an important part of creating and implementing a market development plan
for cancer drugs to insure that the optimal market conditions exist by the
time the products are commercialized.
Table of Contents
Key Topics Covered:
Part I: Lung Cancer
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest
Therapeutic Outcome and Return on Investment (241 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target
Strategies and 416 Lung Cancer Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer
Drugs by Compound Strategy (8 Compound Strategies)
- 9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of
Lung Cancer)
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung
Cancer Drug Pipeline by Investigator (218 Companies)
- 11 Disclaimer
- 12 Drug Index
- 13 Company Index
Part II: Angiogenesis
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (174 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167
Drug Target Strategies and 239 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs
Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies)
- 9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in
Oncology (64 Cancer Indications)
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the
Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148
Investigators)
- 10 Disclaimer
- 11 Drug Index
- 12 Company Index
Part III: Protein Kinase Inhibitors
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (133 Drug Targets)
- 7 The Rise of New Products: How Mature, Unique and Clinically Validated
are the Drug Target Profiles Identified in the Cancer Protein Kinase
Therapeutic Pipeline? (200 Drug Target Strategies and 409 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase
Drugs in Oncology by Compound Type (7 Compound Strategies)
- 9 Selecting Cancer Indications for Protein Kinase Therapeutics (57
Different Cancer Indications)
- 10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer
Therapeutic Pipeline by Investigator (160 Investigators)
- 12 Drug Index
- 13 Company Index
Featured Companies
This Report Includes the Following Companies:
- 4SC
- A&G Pharmaceutical
- Abbott
- Abiogen
- Abraxis BioScience
- Acceleron Pharma
- Access
- ACT Biotech
- Active Biotech
- Adherex
- Advanced Cancer Therapeutics
- Advanomics
- Advantagene
- Advaxis
- Advenchen
- AEgera
- AEterna Zentaris
- Agennix
- Aida Pharmaceuticals
- Alchemia
- Alder Biopharmaceuticals
- Alethia Biotherapeutics
- Alfacell
- Allos Therapeutics
- Alnylam
- AlphaVax
- Altor BioScience
- Ambit Biosciences
- Ambrilia Biopharma
- Amgen
- Amphora
- AngioChem
- Angiogen
- Angiogenex
- Angstrom Pharmaceuticals
- Ansaris
- Antisense Pharma
- Antisoma
- Anza Therapeutics
- ApopLogic Pharmaceuticals
- Apotex
- Apthera
- Arana Therapeutics
- Ariad
- Arno Therapeutics
- ArQule
- Array BioPharma
- Ascenta Therapeutics
- Astellas
- Astex Therapeutics
- AstraZeneca
- Attenuon
- Austrianova
- AVEO
- Avila Therapeutics
- Axelar
- Bayer
- Benitec
- Betapharma
- BioAlliance Pharma
- BioAxone
- Biocompatibles
- Biogen Idec
- Biokine Therapeutics
- BioLineRx
- BioNumerik
- BioSante
- Biotecnol
- Boehringer Ingelheim
- Bolder BioTechnology
- Bristol-Myers Squibb
- BTG
- Calando Pharmaceuticals
- Callisto Pharmaceuticals
- CanBas
- Cancer Research Technology
- CDG Therapeutics
- Celator Pharmaceuticals
- Celecure
- Celgene
- Cell Therapeutics
- CellCeutix
- Cellmid
- Celtic Pharma
- Center of Molecular Immunology
- Cephalon
- CG Therapeutics
- ChemoCentryx
- Chemokine Therapeutics
- China Sky One Medical
- Chong Kun Dang
- Choongwae
- Circadian Technologies
- Clavis Pharma
- CLL Pharma
- CompleGen
- Coronado Biosciences
- Critical Outcome Technologies
- Cue Biotech
- Curaxis
- Curis
- Cyclacel
- Cylene Pharmaceuticals
- Cynvec
- CytImmune Sciences
- Cytochroma
- Cytokinetics
- CytRx
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Dara Biosciences
- Deciphera Pharmaceuticals
- Dendreon
- DeveloGen
- Dong-A
- Dyax
- ECI
- Eisai
- Elara Pharmaceuticals
- Eli Lilly
- Endocyte
- Enkam Pharmaceuticals
- EntreMed
- EpiCept
- Exelixis
- ExonHit Therapeutics
- Facet Biotech
- Five Prime Therapeutics
- Fresenius
- Galapagos
- GammaCan
- Gemin X Biotechnologies
- Genentech
- Generex
- Genmab
- Genta
- GenVec
- Genzyme
- Geron
- Gilead Sciences
- GlaxoSmithKline
- GlobeImmune
- GlycoGenesys
- Gradalis
- Green Cross
- Hanmi
- Hoffmann-La Roche
- Human Genome Sciences
- Hy BioPharma
- Idera Pharmaceuticals
- ImClone Systems
- ImmunoCellular Therapeutics
- Immunocore
- ImmunoFrontier
- ImmunoGen
- Immunomedics
- ImmuPharma
- Incyte Corporation
- Infinity Pharmaceuticals
- Innovive
- Inovio
- Insmed
- Insys Therapeutics
- Intezyne Technologies
- Introgen Therapeutics
- Ipsen
- Isis Pharmaceuticals
- ISU ABXIS
- Jennerex Biotherapeutics
- Johnson & Johnson
- KAI Pharmaceuticals
- Kalypsys
- Karus Therapeutics
- Kiadis
- Kirin Pharma
- Kringle Pharma
- Kyowa Hakko Kirin
- Lee' s Pharmaceutical
- Ligand
- Locus Pharmaceuticals
- Lorus Therapeutics
- MacroGenics
- Marillion Pharmaceuticals
- MAT Biopharma
- MaxoCore Pharmaceuticals
- Meda
- MediGene
- Medisyn Technologies
- Menarini
- Merck & Co
- Merck KGaA
- Merrimack
- Mersana Therapeutics
- MethylGene
- Micromet
- Mirna Therapeutics
- Mitsubishi Tanabe Pharma
- MolMed
- Mologen
- Morvus Technology
- Mycenax
- Nektar Therapeutics
- NeoPharm
- Nereus Pharmaceuticals
- Nerviano Medical Sciences
- Neurocrine Biosciences
- NewSouth Innovations
- NicOx
- Nidus Laboratories
- NIH
- Nippon Kayaku
- Nippon Shinyaku
- Non-industrial source
- Novacea
- Novartis
- Novelix
- Novogen
- Oasmia
- Oncalis
- OncoGenex Pharmaceuticals
- OncoMed
- Onconova
- OncoTherapy Science
- Oncothyreon
- Orchestra Therapeutics
- OSI Pharmaceuticals
- Oxford BioMedica
- OXiGENE
- Paladin Labs
- PanaGin
- PBL Therapeutics
- Pepscan Therapeutics
- PepTx
- Peregrine Pharmaceuticals
- Pfizer
- Pharmacopeia
- Pharmacyclics
- PharmaGap
- PharmaMar
- Pharmexa
- Pharminox
- Philogen
- PhiloGene
- Pierre Fabre
- Piramal
- Plexxikon
- Pro-Pharmaceuticals
- Progen
- Progen Pharmaceuticals
- Protein Sciences
- PTC Therapeutics
- Reata Pharmaceuticals
- Receptor BioLogix
- Regeneron
- Regulon
- RESprotect
- Rexahn
- Rigel
- Samyang
- Sanofi-Aventis
- Santaris Pharma
- Sareum
- SBIO
- Scancell
- Schering-Plough
- SciClone Pharmaceuticals
- Seattle Genetics
- Semafore Pharmaceuticals
- ShimodaAtlantic Oncology
- Shire
- Sigma-Tau
- Silence Therapeutics
- Simcere Pharmaceuticals
- Sirnaomics
- Spear Therapeutics
- SRI International
- SuperGen
- Supratek Pharma
- Switch Pharma
- Symphogen
- SynDevRx
- Synta Pharmaceuticals
- Taiho
- Takeda
- Talon Therapeutics
- Tapestry Pharmaceuticals
- Targa Therapeutics
- TargeGen
- Tau Therapeutics
- Taxolog
- Tekmira Pharmaceuticals
- Telik
- Thallion Pharmaceuticals
- Therion Biologics
- Theryte
- ThromboGenics
- Tigris Pharmaceuticals
- Titan Pharmaceuticals
- ToolGen
- TopoTarget
- Tracon Pharmaceuticals
- Tragara Pharmaceuticals
- Transgene
- TriAct Therapeutics
- Trion Pharma
- UCB
- Valeant
- Vaxon Biotech
- VaxOnco
- VBL Therapeutics
- Vernalis
- Vertex Pharmaceuticals
- Vical
- Wilex
- Vion Pharmaceuticals
- VioQuest Pharmaceuticals
- ViroMed
- Wyeth
- Xencor
- Xerion
- Xoma
- Yakult Honsha
- YM BioSciences
- Zhejiang Beta Pharma
- Zivena
Featured Drugs
A Shortlist of Drugs Included are:
- afatinib
- aflibercept
- alvocidib
- amrubicin hydrochloride
- apatinib
- ARQ-197
- astuprotimut-r
- axitinib
- belagenpumatucel-L
- belotecan hydrochloride
- bevacizumab
- BIBF-1120
- BIBW-2992
- brivanib alaninate
- canfosfamide hydrochloride
- cediranib
- celecoxib
- cetuximab
- cilengitide
- crizotinib
- dacomitinib
- dasatinib
- deforolimus
- docetaxel
- E-75
- emepepimut-S
- endostatin
- enzastaurin hydrochloride
- erlotinib
- etoposide (1)
- etoposide phosphate
- everolimus
- fosbretabulin tromethamine
- gefitinib
- HBP-347
- icotinib hydrochloride
- idronoxil
- imatinib mesilate
- INGN-241
- iniparib
- interferon (gamma1b)
- irinotecan hydrochloride
- lapatinib ditosylate
- lestaurtinib
- linifanib
- midostaurin
- motesanib diphosphate
- nadroparin
- necitumumab
- nilotinib
- nimotuzumab
- oblimersen sodium
- OTS-102
- paclitaxel
- paclitaxel polyglumex
- patupilone
- pazopanib hydrochloride
- pemetrexed disodium
- ramucirumab
- ridaforolimus
- sorafenib tosylate
- sunitinib malate
- talactoferrin alfa
- tanespimycin
- tegafur + uracil
- temsirolimus
- thymalfasin
- tipifarnib
- topotecan
- TS-1
- vandetanib
- XL-184
